Scalper1 News
Generic-drug maker Lannett (LCI) spiked 20% in after-hours trading Wednesday after it announced that it’s acquiring Kremers Urban Pharmaceuticals for $1.23 billion. The buyout will effectively double Lannett’s sales, and boost fiscal 2017 EPS by 20% to 25%, the company said. Kremers, the U.S. arm of Belgium’s UCB, has a portfolio of 18 products, 11 pending applications and 17 candidates in the pipeline. Among them are eight controlled substances, Scalper1 News
Scalper1 News